

DTaP/IPV (KINRIX)

Indications for Use and Schedule

Approved for:

- Routine schedule of one dose at 4-6 years
- Second booster dose of DTaP (5th dose) and IPV (4th dose)
- Ages 4 years through 6 years (6 years, 364 days)

Do not use:

- For dose 1, 2, 3, or 4 of DTaP or dose 1, 2, or 3 of IPV
- In children 7 years of age and older

Make sure minimum age and minimum intervals are met:

- Minimum age for the 5th dose of DTaP is 4 years
- Minimum interval between dose 4 & 5 of DTaP is 6 months

Vaccine Administration

- Intramuscular (IM) injection in the deltoid of the arm or anterolateral thigh
- 1-1 1/4 inch needle; 22-25 gauge
- Use professional judgment when selecting needle length
- Can be given simultaneously with other vaccines (use separate sites; space at least 1 inch apart)

Storage and Handling

- Store in the refrigerator between 35°-46° F (2°-8°C)
- Do NOT freeze
- Keep in the original box
- Shake well before use



CONTRAINDICATIONS

- An anaphylactic reaction to a prior dose of DTaP/IPV (Kinrix™), DTaP or IPV
- An anaphylactic reaction to a component of DTaP/IPV (Kinrix™) including neomycin or polymyxin B
- Encephalopathy not due to another cause occurring within 7 days after vaccination with a Pertussis-containing vaccine
- Progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy or progressive encephalopathy)

PRECAUTIONS:

- Moderate to severe acute illness
- Guillain-Barre syndrome within 6 weeks of a prior vaccine containing tetanus toxoid
- Precautions specific to DTaP vaccine
- Temperature greater than or equal to 105°F within 48 hours of vaccination with no other identifiable cause
- Collapse or shock-like state within 48 hours of vaccination
- Persistent inconsolable crying lasting more than 3 hours within 48 hours of vaccination
- Convulsions with or without a fever within 3 days of vaccination

FURTHER POINTS

- The second booster dose of DTaP (5th dose) is not necessary if the 4th dose of DTaP is administered on or after the 4th birthday
- DTaP/IPV (Kinrix™) does not contain a preservative. After removal of the dose, any remaining vaccine should be discarded.
- The combined DTaP/IPV vaccine may be used when any component of the vaccine is indicated, and if the other components are not contraindicated
- There is not a separate Vaccine Information Statement (VIS) for DTaP/IPV (Kinrix™). Use the current VISs for DTaP and IPV.

Publicly purchased DTaP/IPV (Kinrix™) can be administered to eligible children 4 through 6 years of age through the Vaccines for Children (VFC) Program in private providers' office. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information.

For additional information, refer to VFC Program Resolutions on "Vaccines to Prevent Diphtheria, Tetanus and Pertussis" and "Vaccines to Prevent Poliomyelitis" and the ACIP Recommendations on the use of DTaP and IPV vaccines, located at <http://www.cdc.gov/vaccines/recs>